GO:0000381 regulation of alternative mRNA splicing, via spliceosome: Splice Site Selection, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000381 describes any process that modulates the frequency, rate or extent of alternative splicing of nuclear mRNAs, including splice site selection.
• The spliceosome is a dynamic ribonucleoprotein machine that catalyzes intron removal and exon ligation, and its regulation determines which mRNA isoforms are produced.
• Alternative splicing regulation expands proteome diversity and is controlled by cis-elements, trans-acting splicing factors, and signaling pathways.
• Dysregulation of alternative splicing regulation is linked to cancer progression, chemoresistance, neurodegeneration, autoimmunity, and innate inflammation.
• Core regulators include SF3B3, BRD4, WAC, and U12-type splicing components, which influence mTOR signaling, mitophagy, inflammation, and lupus neutrophils.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of splicing regulators in disease-relevant cell systems.
Description
GO:0000381, regulation of alternative mRNA splicing, via spliceosome, is a biological process ontology term that captures any mechanism modulating the frequency, rate, or extent of alternative splicing of nuclear mRNAs. Alternative splicing allows a single pre-mRNA to generate multiple mature mRNA isoforms, and its regulation is central to gene expression, proteome diversity, and cellular adaptation. The spliceosome, a large ribonucleoprotein complex, performs the chemistry of intron removal and exon ligation, while regulatory factors influence splice site selection and isoform ratios. Because splicing decisions are responsive to developmental, metabolic, and stress signals, their dysregulation can reprogram cell behavior in disease. Researchers study GO:0000381 to understand how specific splicing factors, RNA-binding proteins, and signaling pathways control isoform production and to identify therapeutic vulnerabilities. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanisms, key genes, disease links, and experimental methods relevant to GO:0000381.
regulation of alternative mRNA splicing, via spliceosome At A Glance
| GO ID | GO:0000381 |
|---|---|
| GO term | regulation of alternative mRNA splicing, via spliceosome |
| Ontology | biological_process |
| Synonym | regulation of alternative nuclear mRNA splicing, via spliceosome; splice site selection |
| Major function | Modulates the frequency, rate or extent of alternative splicing of nuclear mRNAs, including splice site selection |
| Cellular context | Nucleus; spliceosome and associated ribonucleoprotein complexes |
| Key molecular players | Spliceosomal snRNPs, SF3B3, BRD4, WAC, and U12-type splicing components |
| Disease relevance | Cancer, chemoresistance, Alzheimer's disease, lupus, and innate inflammation |
What Is GO:0000381?
In plain terms, GO:0000381 refers to the cellular processes that adjust how often and how efficiently alternative splicing occurs in nuclear mRNAs. The QuickGO definition states: Any process that modulates the frequency, rate or extent of alternative splicing of nuclear mRNAs. This includes regulation of splice site selection, meaning the choice among competing splice sites that determines which exons are included or excluded in the final mRNA. The term is a biological process and is not restricted to a single protein; it encompasses cis-regulatory RNA elements, trans-acting splicing factors, and signaling events that alter spliceosome activity or recruitment.
Why Is regulation of alternative mRNA splicing, via spliceosome Important in Cell Biology?
Regulation of alternative mRNA splicing, via spliceosome, is essential because it determines the mRNA isoform landscape of a cell and thereby influences protein function, signaling output, and stress responses. Because the spliceosome is a central node for gene expression, changes in its regulation can simultaneously affect many pathways, including mTOR signaling, mitophagy, innate immunity, and neuronal function. Consequently, understanding GO:0000381 is important for interpreting disease mechanisms and for designing experiments that test causal roles of splicing regulators in specific cell types.
• Controls proteome diversity by determining which exons are included in mature mRNAs.
• Integrates cellular signals such as growth, stress, and immune cues into splicing decisions.
• Dysregulation is associated with cancer progression and metastasis, including SF3B3-regulated mTOR alternative splicing.
• Altered splicing regulation contributes to chemoresistance in cancer cells.
• Alternative splicing changes are observed in Alzheimer's disease and other neurodegenerative conditions.
• U12-type splicing dysregulation has been reported in lupus neutrophils, linking splicing to autoimmunity.
• BRD4-dependent regulation of alternative splicing modulates innate inflammation.
• Nuclear condensates of WAC regulate mitophagy via alternative splicing, showing spatial control of splicing.
• Spliceosome-mediated splicing mechanisms are conserved and studied in model organisms such as Saccharomyces cerevisiae.
• Splicing regulators are candidate therapeutic targets and biomarkers in multiple disease contexts.
What Happens During regulation of alternative mRNA splicing, via spliceosome?
Spliceosome assembly and catalytic activation
In simple terms: The spliceosome is built step by step on the pre-mRNA, like a machine assembling around the intron before it cuts and joins RNA pieces.
The spliceosome is a dynamic ribonucleoprotein complex that assembles on pre-mRNA through sequential recruitment of small nuclear ribonucleoproteins (snRNPs) and associated proteins. In Saccharomyces cerevisiae and other systems, spliceosome-mediated pre-mRNA splicing involves coordinated rearrangements that position the branch point, 5' splice site, and 3' splice site for catalysis. Regulation of alternative splicing occurs when these assembly or catalytic steps are modulated, altering which splice sites are used and thus which mRNA isoforms are produced.
Splice site selection and exon definition
In simple terms: The cell chooses which splice sites to use, like selecting which paragraphs to keep or skip when editing a text.
Splice site selection is a key component of GO:0000381 and determines whether a given exon is included or skipped. Cis-acting RNA elements and trans-acting splicing factors influence the recognition of splice sites by the spliceosome, thereby modulating alternative splicing frequency and isoform ratios. This regulatory layer allows the same pre-mRNA to yield different mature mRNAs in different cell states or conditions.
Coupling to signaling and nuclear organization
In simple terms: Splicing decisions are not isolated; they respond to signals and where components are located in the nucleus.
Regulation of alternative splicing is coupled to cellular signaling and nuclear organization. For example, nuclear condensates of WW domain-containing adaptor with coiled-coil (WAC) regulate mitophagy via alternative splicing, indicating that spatial compartmentalization can control splicing outcomes. SF3B3-regulated mTOR alternative splicing links spliceosome components to growth signaling and cancer progression. These examples show that GO:0000381 integrates signaling and nuclear architecture to shape mRNA isoform production.
Immune and inflammatory splicing programs
In simple terms: Immune cells also use alternative splicing to fine-tune inflammatory responses.
Bromodomain-containing protein 4 (BRD4) regulates innate inflammation via modulation of alternative splicing, demonstrating that splicing regulation is part of immune gene expression programs. Dysregulation of U12-type splicing has been observed in lupus neutrophils, further connecting splicing regulation to autoimmune pathology. These findings support the view that GO:0000381 is relevant to both homeostatic and pathological immune responses.
Disease-associated splicing reprogramming
In simple terms: When splicing regulation goes wrong, it can contribute to diseases such as cancer and neurodegeneration.
Alternative splicing dysregulation is associated with Alzheimer's disease, where changes in splicing regulation may affect neuronal function. In cancer, regulation of alternative mRNA splicing can influence chemoresistance and metastatic behavior. These disease links highlight why researchers study GO:0000381 to identify mechanisms and potential intervention points.
Key Genes Involved in GO:0000381 regulation of alternative mRNA splicing, via spliceosome
The following genes and proteins are experimentally implicated in the regulation of alternative mRNA splicing, via spliceosome (GO:0000381), based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SF3B3 | Spliceosome component regulating mTOR alternative splicing | Promotes colorectal cancer progression and metastasis |
| BRD4 | Chromatin reader modulating alternative splicing | Regulates innate inflammation via splicing |
| WAC | Nuclear condensate component linked to mitophagy | Regulates mitophagy via alternative splicing |
| U12-type splicing components | Minor spliceosome machinery | Dysregulated in lupus neutrophils |
| Spliceosomal snRNPs | Core spliceosome assembly and catalysis | Central to spliceosome-mediated pre-mRNA splicing |
| mTOR pathway genes | Signaling output affected by alternative splicing | Linked to SF3B3-regulated splicing in cancer |
| Alzheimer's disease-associated splicing factors | Neuronal splicing regulation | Implicated in alternative splicing changes in Alzheimer's disease |
| Chemoresistance-associated splicing regulators | Modulate drug response via isoforms | Studied in cancer chemoresistance |
| Innate immunity splicing factors | Immune gene isoform regulation | BRD4-dependent regulation of innate inflammation |
| Lupus neutrophil splicing factors | U12-type splicing regulation | Associated with lupus neutrophil dysregulation |
| Saccharomyces cerevisiae splicing factors | Model organism spliceosome components | Used to study spliceosome-mediated splicing mechanisms |
| Pre-mRNA cis-elements | Splice site selection signals | Determine alternative splicing outcomes |
| Trans-acting splicing factors | Modulate splice site choice | Key regulators of GO:0000381 |
| Nuclear condensate proteins | Spatial organization of splicing | WAC condensates regulate mitophagy via splicing |
| Signaling kinases | Couple signals to splicing | mTOR signaling intersects with SF3B3-regulated splicing |
| RNA-binding proteins | Sequence-specific splicing regulation | General regulators of alternative splicing |
| Spliceosome assembly factors | Facilitate snRNP rearrangements | Required for catalytic activation |
How Is regulation of alternative mRNA splicing, via spliceosome Regulated?
Regulation of alternative mRNA splicing, via spliceosome, is itself controlled by multiple layers. Signaling pathways such as mTOR intersect with spliceosome components like SF3B3 to influence alternative splicing of mTOR-related transcripts. Chromatin-associated factors such as BRD4 can modulate alternative splicing and thereby innate inflammation. Nuclear condensates containing WAC provide spatial regulation of splicing and mitophagy. In autoimmune contexts, U12-type splicing dysregulation in lupus neutrophils indicates that splicing regulation can be altered in disease-specific ways. These examples illustrate that GO:0000381 is responsive to growth, immune, and spatial cues.
regulation of alternative mRNA splicing, via spliceosome and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SF3B3 | Colorectal cancer progression and metastasis | Knockout or knockdown in colorectal cancer cell lines |
| BRD4 | Innate inflammation | Knockout or point-mutation in immune cell models |
| WAC | Mitophagy regulation | Knockout or tagged knock-in in mammalian cells |
| U12-type splicing components | Lupus neutrophils | Knockout or overexpression in neutrophil-like cells |
| Splicing regulators in chemoresistance | Cancer drug response | Overexpression or knockout in chemoresistant cancer lines |
Cancer progression and chemoresistance
SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis, linking GO:0000381 to tumor biology. Regulation of chemoresistance via alternative messenger RNA splicing further supports the idea that splicing regulation influences drug response in cancer. These findings suggest that targeting splicing regulators could alter cancer cell phenotypes.
Neurodegeneration
Alternative splicing in Alzheimer's disease has been reviewed as a contributor to neuronal dysfunction, indicating that GO:0000381 is relevant to neurodegenerative mechanisms. Changes in splicing regulation may affect proteins critical for neuronal survival and function.
Autoimmunity and inflammation
Dysregulation of U12-type splicing in lupus neutrophils connects splicing regulation to autoimmune pathology. BRD4 regulates innate inflammation via modulation of alternative splicing, showing that GO:0000381 participates in immune responses. Together, these studies highlight splicing regulation as a component of inflammatory and autoimmune disease mechanisms.
From regulation of alternative mRNA splicing, via spliceosome-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a splicing regulator alter isoform ratios? | CRISPR knockout cell line followed by RNA-seq |
| Does a specific point mutation in a splicing factor change splice site selection? | CRISPR point-mutation knock-in cell line |
| Can a disease-associated isoform be restored? | Knock-in of specific splice isoform or minigene reporter |
| Where does a splicing regulator localize in the nucleus? | Tagged knock-in with fluorescent tag and imaging |
| Does overexpression of a splicing factor drive a disease phenotype? | Overexpression cell model in disease-relevant cells |
| Which splicing events are controlled by a candidate regulator? | CRISPR knockout plus transcriptome-wide splicing analysis |
How to Study the regulation of alternative mRNA splicing, via spliceosome Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome-wide isoform expression | Identify alternative splicing changes after perturbation |
| Minigene reporter assay | Splice site selection for a specific event | Test regulatory elements and factors |
| CLIP or RIP | RNA binding sites of splicing factors | Map interactions of regulators with pre-mRNA |
| Fluorescence imaging | Nuclear localization and condensates | Study spatial regulation of splicing |
| CRISPR knockout | Loss-of-function effects on splicing | Test causal role of candidate regulators |
| CRISPR point mutation | Effect of specific amino acid changes | Dissect domain functions in splicing factors |
| Overexpression | Gain-of-function effects on isoforms | Model disease-associated splicing changes |
| Proteomics | Protein interactions and complexes | Characterize spliceosome-associated proteins |
RNA-seq and isoform quantification
RNA sequencing enables transcriptome-wide measurement of alternative splicing events and isoform ratios, which is essential for studying GO:0000381. By comparing control and perturbed cells, researchers can identify splicing changes associated with specific regulators such as SF3B3 or BRD4.
Spliceosome and ribonucleoprotein analysis
Biochemical and structural studies of the spliceosome reveal how snRNPs and associated proteins assemble and catalyze splicing, providing mechanistic insight into regulation. Model organisms such as Saccharomyces cerevisiae are used to dissect conserved spliceosome-mediated splicing mechanisms.
Imaging of nuclear condensates
Fluorescence imaging of tagged proteins can reveal nuclear condensates and their relationship to splicing regulation, as shown for WAC condensates regulating mitophagy via alternative splicing. This approach helps connect spatial organization to GO:0000381.
Disease-relevant functional assays
Functional assays in cancer, immune, and neuronal cell models can test whether splicing regulators affect proliferation, metastasis, inflammation, or neuronal phenotypes. Such assays link molecular splicing changes to disease biology.
How CRISPR Can Be Used to Study GO:0000381 regulation of alternative mRNA splicing, via spliceosome
Knockout
CRISPR knockout of splicing regulators such as SF3B3 or BRD4 can reveal their requirement for specific alternative splicing events and downstream phenotypes. Knockout models are useful for testing whether a candidate gene is causally involved in GO:0000381-related processes.
Point Mutation
Point mutations introduced by CRISPR can dissect functional domains of splicing factors and their impact on splice site selection. Such models help distinguish catalytic versus regulatory functions within GO:0000381.
Knock-in
Knock-in of tagged or disease-associated variants allows tracking of splicing regulators and testing of specific isoforms in disease contexts. Tagged knock-in can also enable imaging of nuclear condensates involved in splicing regulation.
Overexpression
Overexpression models can mimic gain-of-function states observed in cancer or inflammation and test whether increased levels of a splicing regulator alter isoform ratios. These models complement loss-of-function studies to establish causality in GO:0000381.
How EDITGENE Supports regulation of alternative mRNA splicing, via spliceosome Research
Researchers studying regulation of alternative mRNA splicing, via spliceosome-related genes often need to determine whether a candidate gene is causally involved in splice site selection, isoform production, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable such causal tests in relevant cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for regulation of alternative mRNA splicing, via spliceosome research.
Frequently Asked Questions About regulation of alternative mRNA splicing, via spliceosome
What is GO:0000381?
GO:0000381 is the Gene Ontology term for regulation of alternative mRNA splicing, via spliceosome, defined as any process that modulates the frequency, rate or extent of alternative splicing of nuclear mRNAs.
What does regulation of alternative mRNA splicing, via spliceosome mean?
It refers to cellular mechanisms that control splice site selection and isoform production by the spliceosome, thereby influencing which mRNA variants are made.
What genes are involved in regulation of alternative mRNA splicing, via spliceosome?
Genes and proteins implicated include SF3B3, BRD4, WAC, spliceosomal snRNPs, and U12-type splicing components, among others.
How is alternative splicing regulated by the spliceosome?
The spliceosome assembles on pre-mRNA and catalyzes intron removal, while regulatory factors and signaling pathways modulate splice site selection and catalytic steps.
Why is GO:0000381 important in cancer?
SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis, and splicing regulation can influence chemoresistance.
Is alternative splicing regulation involved in Alzheimer's disease?
Yes, alternative splicing changes have been described in Alzheimer's disease, suggesting a role for splicing regulation in neurodegeneration.
What is the role of BRD4 in alternative splicing?
BRD4 regulates innate inflammation via modulation of alternative splicing, linking chromatin-associated factors to splicing regulation.
How can CRISPR be used to study GO:0000381?
CRISPR knockout, point mutation, knock-in, and overexpression can test causal roles of splicing regulators in isoform production and disease phenotypes.
What methods are used to study regulation of alternative mRNA splicing?
Common methods include RNA-seq, minigene reporters, CLIP/RIP, imaging, and proteomics to measure isoform changes and regulator interactions.
What diseases are linked to dysregulated splicing regulation?
Cancer, chemoresistance, Alzheimer's disease, lupus, and innate inflammation have been associated with altered splicing regulation.
Conclusion
GO:0000381, regulation of alternative mRNA splicing, via spliceosome, is a central biological process that controls mRNA isoform diversity and cellular responses to signals. Its dysregulation is implicated in cancer, neurodegeneration, autoimmunity, and inflammation, making it a key area for mechanistic and translational research. CRISPR-based cell models and transcriptome-wide methods provide powerful tools to dissect how specific regulators control splice site selection and disease phenotypes.
References
- 1. Matera AG et al.. 2014. A day in the life of the spliceosome.. Nat Rev Mol Cell Biol 15(2):108-21 PMID: 24452469
- 2. Senn KA et al.. 2024. Mechanisms and regulation of spliceosome-mediated pre-mRNA splicing in Saccharomyces cerevisiae.. Wiley Interdiscip Rev RNA 15(4):e1866 PMID: 38972853
- 3. Xu T et al.. 2024. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.. J Exp Clin Cancer Res 43(1):126 PMID: 38671459
- 4. Wang J et al.. 2025. Nuclear Condensates of WW Domain-Containing Adaptor With Coiled-Coil Regulate Mitophagy via Alternative Splicing.. Adv Sci (Weinh) 12(10):e2406759 PMID: 39840526
- 5. Biamonti G et al.. 2021. Alternative splicing in Alzheimer's disease.. Aging Clin Exp Res 33(4):747-758 PMID: 31583531
- 6. Eblen ST. 2012. Regulation of chemoresistance via alternative messenger RNA splicing.. Biochem Pharmacol 83(8):1063-72 PMID: 22248731
- 7. Mann MW et al.. 2023. Bromodomain-containing Protein 4 regulates innate inflammation via modulation of alternative splicing.. Front Immunol 14:1212770 PMID: 37435059
- 8. Blanco LP et al.. 2026. Dysregulation of U12-Type Splicing in Lupus Neutrophils.. Arthritis Rheumatol 78(7):1490-1499 PMID: 41524512
